Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1323)	5/15/2002 2:22:14 AM
From: scaram(o)uche	Respond to of 1475

cool! from John2451 in the yahoo thread...... ausbiotech.org Key Events in 2000-2001 • Reincorporated as an Australian public unlisted company • A$3.75 Million capital raising completed • Independent facilities established in UK • First full-time staff appointed (Aust and UK) • Assisted in securing £2.8M UK government stem cell grant for CGR (Edinburgh University) • Major Aventis milestone reached (technology proven) • Key US patents granted • Closed second major Pharma deal

To: scaram(o)uche who wrote (1323)	5/15/2002 8:57:13 AM
From: Arthur Radley	Read Replies (2) \| Respond to of 1475

Rick, Concerning the issue of T-cell depletion with siplizumab and the dosing regimen that MEDI has undertaken in the current trials, could you help me understand this issue as it relates to the purposed new indication for RA. 1) Would the dosing regimen necessarily be the same for psoriasis as for RA? 2) "If" they actually undertake clinical trials with this new indication, would it not be safe to assume that at least they have some anecdotal evidence that the depletion issue isn't that great? 3) Concerning the start of the retreatment studies, would it not be logical to assume that MEDI had to provide some data to the FDA for them to approve such retreatments and if so, wouldn't an issue of depletion preclude such retreatments? Or, would the initial protocol agreement with the FDA allow for retreatments, without any updated data? As always...thanks for your input. And thanks for the congrats on my daughter!